Network Pharmacology Combined With Metabolomics Reveals the Mechanism of Yangxuerongjin Pill Against Type 2 Diabetic Peripheral Neuropathy in Rats
Jin Ran,
No information about this author
Hailuan Pei,
No information about this author
Feng Yue
No information about this author
et al.
Drug Design Development and Therapy,
Journal Year:
2025,
Volume and Issue:
Volume 19, P. 325 - 347
Published: Jan. 1, 2025
This
study
aims
to
explore
the
mechanism
of
Yangxuerongjin
pill
(YXRJP)
in
treatment
diabetic
peripheral
neuropathy
(DPN)
by
network
pharmacology
and
metabolomics
technology
combined
with
animal
experiments,
provide
scientific
basis
for
DPN.
In
this
study,
analysis
was
applied
identify
active
compounds,
core
targets
signal
pathways,
which
might
be
responsible
effect
The
DPN
model
established
high-fat
diet
streptozotocin
(STZ)
injection,
rats
were
given
administration
12
weeks.
body
weight,
thermal
withdrawal
latency
(TWL),
sciatic
motor
nerve
conduction
velocity
(MNCV),
biochemical
indexes,
pathological
sections
nerve,
oxidative
stress
factors
expression
levels
neuroprotection-related
proteins
detected.
Metabolomics
used
analyze
potential
biomarkers
metabolic
pathways
treated
YXRJP.
results
showed
that
YXRJP
could
treat
through
baicalin,
β-sitosterol,
7-methoxy-2-methylisoflavone,
aloe-emodin
luteolin
on
insulin
resistance,
Toll-like
receptor
(TLR),
tumor
necrosis
factor
(TNF)
other
signaling
pathways.
can
prolong
TWL,
increase
MNCV
alleviate
injury
reduce
triglyceride
(TG),
improve
Insulin-like
growth
1
(IGF-1)
protein
kinase
B
(AKT)
protein.
mainly
involved
amino
acid
metabolism
such
as
arginine,
alanine,
aspartic
acid,
lipid
nucleotide
metabolism.
effectively
symptoms
damage.
effects
are
related
reducing
injury,
promoting
proteins,
inflammation-related
affecting
metabolism,
Our
findings
revealed
has
a
good
therapeutic
DPN,
provides
reference
further
studies
Language: Английский
Whether coagulation dysfunction influences the onset and progression of diabetic peripheral neuropathy: A multicenter study in middle‐aged and aged patients with type 2 diabetes
Jiali Xie,
No information about this author
Xinyue Yu,
No information about this author
Luowei Chen
No information about this author
et al.
CNS Neuroscience & Therapeutics,
Journal Year:
2024,
Volume and Issue:
30(9)
Published: Sept. 1, 2024
Abstract
Background
Nearly
half
of
patients
with
diabetes
experience
diabetic
peripheral
neuropathy
(DPN),
resulting
in
a
mere
53%
survival
rate
within
3
years.
Aberrations
coagulation
function
have
been
implicated
the
pathogenesis
microvascular
complications,
prompting
need
for
thorough
investigation
into
its
role
as
contributing
factor
development
and
progression
DPN.
Methods
Data
were
gathered
from
1211
type
2
admitted
to
five
centers
September
2018
October
2022
China.
DPN
was
evaluated
by
symptoms
electromyography.
Motor
sensory
nerve
conduction
velocity
(NCV)
appraised
NCV
sum
score
calculated
median,
ulnar,
peroneal
motor
or
nerves.
Results
Patients
exhibited
alterations
function.
(i)
Specifically,
they
prolonged
thrombin
time
(
p
=
0.012),
elevated
fibrinogen
<
0.001),
shortened
activated
partial
thromboplastin
(APTT;
0.026)
when
compared
control
group.
(ii)
After
accounting
potential
confounders
linear
regression,
fibrinogen,
D‐dimer
negatively
related
NCV,
amplitude
values,
mean
amplitude.
Also,
associated
higher
Michigan
screening
instrument
(MNSI)
scores
β
0.140;
0.001).
This
result
can
be
validated
validation
cohort
317
patients.
(iii)
Fibrinogen
independently
risk
(OR
1.172;
0.035).
In
total
age
group,
occurred
at
slower
until
predicted
level
reached
around
3.75
g/L,
after
which
sharply
escalated.
Conclusions
Coagulation
is
warranted
concerned
predict
prevent
occurrence
clinical
practice.
Language: Английский
Comparative efficacy and safety of Chinese patent medicines as an adjunctive therapy for diabetic peripheral neuropathy: systematic review and network meta-analysis of randomized controlled trials
Pharmaceutical Biology,
Journal Year:
2024,
Volume and Issue:
62(1), P. 833 - 852
Published: Nov. 4, 2024
Context
Diabetic
peripheral
neuropathy
(DPN)
is
the
most
common
complication
of
diabetes
mellitus.
Chinese
patent
medicines
(CPMs)
are
widely
used
in
clinical
practice
to
treat
DPN.
Language: Английский
Pharmacological Effects of Paeonia lactiflora Focusing on Painful Diabetic Neuropathy
V. Wiegand,
No information about this author
Ying Gao,
No information about this author
Nicole Teusch
No information about this author
et al.
Planta Medica,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Oct. 29, 2024
Abstract
Painful
diabetic
neuropathy
(PDN)
is
a
highly
prevalent
complication
in
patients
suffering
from
diabetes
mellitus.
Given
the
inadequate
pain-relieving
effect
of
current
therapies
for
PDN,
there
high
unmet
medical
need
specialized
therapeutic
options.
In
traditional
Chinese
medicine
(TCM),
various
herbal
formulations
have
been
implemented
centuries
to
relieve
pain,
and
one
commonly
used
plant
this
context
Paeonia
lactiflora
(P.
lactiflora).
Here,
we
summarize
chemical
constituents
P.
including
their
pharmacological
mechanisms-of-action
discuss
potential
benefits
treatment
PDN.
For
this,
silico
data,
as
well
preclinical
clinical
studies,
were
critically
reviewed
comprehensively
compiled.
Our
findings
reveal
that
its
individual
exhibit
variety
properties
relevant
antinociceptive,
anti-inflammatory,
antioxidant,
antiapoptotic
activities.
Through
multifaceted
complex
combination
effects,
hallmarks
PDN
are
specifically
addressed,
suggesting
may
represent
promising
source
novel
approaches
Language: Английский